炭疽病ワクチンの世界市場レポート 2025年

炭疽病ワクチン市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.1％で145億米ドルに成長します。予測期間の成長は、世界のセキュリティ課題、新たな脅威、政府調達イニシアティブ、パンデミック対策に起因しています。予測期間の主な動向としては、技術の進歩、発展途上国におけるアクセスの向上、次世代ワクチンへの注力、政府備蓄の増加、共同研究への取り組みなどが挙げられます。

炭疽病ワクチン市場は、感染症の流行の高まりにより大きな成長が見込まれています。様々な病原体によって引き起こされる感染症は、公衆衛生に大きな脅威をもたらし、様々な症状や時には致命的な結果をもたらします。感染症の流行増加の要因としては、人口動態の変化、都市化、環境の変化、人間の行動の変化などが挙げられます。主に炭疽菌から身を守るために開発された炭疽病ワクチンは、現在進行中の免疫原性と適応性の調査によって、他の感染症予防の可能性が模索されています。2023年2月に外交問題評議会（Council on Foreign Relations）が強調したように、新たに発見された感染症や新興感染症のかなりの割合が人獣共通感染症を起源としており、その影響を緩和するための効果的なワクチンの必要性が強調されています。

炭疽病ワクチン市場の主要企業は、炭疽菌に暴露されるリスクのある人々のために、安全性、有効性、入手しやすさを確保するために、革新的な製品の開発とFDA承認の取得を優先しています。FDAの承認は、ワクチンが臨床試験で厳格なテストを受け、一般に使用しても安全であると判断されたことを意味し、その安全性プロファイルについて個人に保証を与えるものです。例えば、バイオ医薬品の主要企業であるEmergent BioSolutions Inc.は、2023年7月にCYFENDUS（炭疽病ワクチンAdsorbed, Adjuvanted）のFDA承認を取得しました。この承認は、既存の炭疽ワクチンと比較してワクチンの安全性と免疫原性を評価した包括的な第2相および第3相臨床試験に基づいています。さらに、アジュバント技術の進歩は、反応原性の懸念に対処し、炭疽ワクチンの全体的な有効性を高めるために極めて重要です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界炭疽病ワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の炭疽病ワクチン市場：成長率分析
• 世界の炭疽病ワクチン市場の実績：規模と成長, 2019-2024
• 世界の炭疽病ワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界炭疽病ワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の炭疽病ワクチン市場ワクチンの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細胞遊離型防御抗原（PA）ワクチン
• 生弱毒化ワクチン
• 世界の炭疽病ワクチン市場アプリケーションタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 動物の使用
• 人間の使用
• 世界の炭疽病ワクチン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 薬局
• その他の流通チャネル
• 世界の炭疽病ワクチン市場細胞遊離型防御抗原（PA）ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換え防御抗原（rPA）ワクチン
• アジュバント添加rPAワクチン
• 世界の炭疽病ワクチン市場生弱毒化ワクチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生弱毒化炭疽菌ワクチン
• 遺伝子組み換え生弱毒化ワクチン

第7章 地域別・国別分析

• 世界の炭疽病ワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の炭疽病ワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 炭疽病ワクチン市場：競合情勢
• 炭疽病ワクチン市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GC Biopharma Overview, Products and Services, Strategy and Financial Analysis
  • Emergent BioSolutions Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Indian Immunologicals Limited Overview, Products and Services, Strategy and Financial Analysis
  • Valneva SE Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• PharmAthene Inc
• Porton Biopharma Limited
• Pfenex Inc.
• Choong Ang Vaccine Laboratories Co. Ltd.
• Colorado Serum Company, Inc.
• Elusys Therapeutics Inc.
• SIGA Technologies Inc.
• Inovio Pharmaceuticals
• Botswana Vaccine Institute
• JOVAC
• Prokarium
• Soligenix Inc.
• Vaxart Inc.
• DynPort Vaccine Company LLC
• VECOL S.A

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 炭疽病ワクチン市場2029：新たな機会を提供する国
• 炭疽病ワクチン市場2029：新たな機会を提供するセグメント
• 炭疽病ワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The anthrax vaccine is a medical product aimed at conferring immunity against anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis. Comprising an inactivated form of the anthrax bacterium or its components, the vaccine stimulates the body's immune response to generate antibodies against anthrax toxins. Typically administered via injections, the vaccine involves initial doses followed by booster shots to sustain immunity over time.

The primary types of anthrax vaccine include the cell-free protective antigen (PA) vaccine and the live attenuated vaccine. The cell-free protective antigen (PA) vaccine is produced in a laboratory environment without live bacteria, involving the synthesis of the anthrax bacteria's protective antigen (PA) protein. These vaccines find applications in both animal and human use and are distributed through various channels such as hospitals, pharmacies, and others.

The anthrax vaccine market research report is one of a series of new reports from The Business Research Company that provides anthrax vaccine market statistics, including anthrax vaccine industry global market size, regional shares, competitors with a anthrax vaccine market share, detailed anthrax vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the anthrax vaccine industry. This anthrax vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anthrax vaccine market size has grown strongly in recent years. It will grow from $11.27 billion in 2024 to $11.88 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to biological warfare concerns, military demand, anthrax outbreaks, public health preparedness, and biodefense programs.

The anthrax vaccine market size is expected to see strong growth in the next few years. It will grow to $14.5 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to global security challenges, emerging threats, government procurement initiatives, pandemic preparedness. Major trends in the forecast period include technological advancements, greater accessibility in developing countries, focus on next-generation vaccines, increased government stockpiling, collaborative research efforts.

The anthrax vaccine market is expected to experience significant growth due to the rising prevalence of infectious diseases. Infectious diseases, caused by various pathogens, pose a significant threat to public health, leading to a range of symptoms and sometimes fatal outcomes. Factors contributing to the increased prevalence of infectious diseases include demographic shifts, urbanization, environmental changes, and alterations in human behavior. The anthrax vaccine, primarily designed to protect against anthrax, is being explored for its potential to prevent other infectious diseases, driven by ongoing research into its immunogenic properties and adaptability. As highlighted by the Council on Foreign Relations in February 2023, a considerable percentage of newly discovered or emerging infectious diseases have zoonotic origins, underscoring the need for effective vaccines to mitigate their impact.

Major companies in the anthrax vaccine market are prioritizing the development of innovative products and obtaining FDA approvals to ensure safety, efficacy, and accessibility for individuals at risk of anthrax exposure. FDA approval signifies that a vaccine has undergone rigorous testing in clinical trials and has been deemed safe for public use, providing assurance to individuals regarding its safety profile. For example, Emergent BioSolutions Inc., a leading biopharmaceutical company, received FDA approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) in July 2023. This approval was based on comprehensive Phase 2 and Phase 3 clinical trials evaluating the vaccine's safety and immunogenicity compared to existing anthrax vaccines. Additionally, advancements in adjuvant technology are crucial for addressing reactogenicity concerns and enhancing the overall effectiveness of anthrax vaccines.

In October 2022, the Biomedical Advanced Research and Development Authority (BARDA) partnered with ICON plc and Rho Federal Systems Division Inc. to conduct a clinical trial evaluating the anthrax vaccine AV7909. This trial aims to assess the immunogenicity kinetics of AV7909, which combines the FDA-licensed anthrax vaccine BioThrax with an immune system stimulant. ICON plc, an Ireland-based clinical research organization, and Rho Federal Systems Division Inc., a US-based company specializing in research and development services, are collaborating with BARDA to advance anthrax vaccine research and development.

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc, Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A.

North America was the largest region in the anthrax vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anthrax vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anthrax vaccine market consists of sales of avirulent, nonencapsulated bacillus anthracis microaerophilic cultures, aluminum, benzethonium chloride, and formaldehyde. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anthrax Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anthrax vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anthrax vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anthrax vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine; Live Attenuated Vaccine
• 2) By Application Type: Animal Use; Human Use
• 3) By Distribution Channel: Hospitals; Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine; Adjuvanted rPA Vaccine
• 2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine; Genetically Modified Live Attenuated Vaccine
• Companies Mentioned: Merck & Co. Inc.; GC Biopharma; Emergent BioSolutions Inc.; Indian Immunologicals Limited; Valneva SE
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anthrax Vaccine Market Characteristics

3. Anthrax Vaccine Market Trends And Strategies

4. Anthrax Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Anthrax Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anthrax Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anthrax Vaccine Market Growth Rate Analysis
• 5.4. Global Anthrax Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anthrax Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anthrax Vaccine Total Addressable Market (TAM)

6. Anthrax Vaccine Market Segmentation

• 6.1. Global Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cell-Free Protective Antigen (PA) Vaccine
• Live Attenuated Vaccine
• 6.2. Global Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Animal Use
• Human Use
• 6.3. Global Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Pharmacies
• Other Distribution Channels
• 6.4. Global Anthrax Vaccine Market, Sub-Segmentation Of Cell-Free Protective Antigen (PA) Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Protective Antigen (rPA) Vaccine
• Adjuvanted rPA Vaccine
• 6.5. Global Anthrax Vaccine Market, Sub-Segmentation Of Live Attenuated Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Live Attenuated Bacillus anthracis Vaccine
• Genetically Modified Live Attenuated Vaccine

7. Anthrax Vaccine Market Regional And Country Analysis

• 7.1. Global Anthrax Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anthrax Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anthrax Vaccine Market

• 8.1. Asia-Pacific Anthrax Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anthrax Vaccine Market

• 9.1. China Anthrax Vaccine Market Overview
• 9.2. China Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anthrax Vaccine Market

• 10.1. India Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anthrax Vaccine Market

• 11.1. Japan Anthrax Vaccine Market Overview
• 11.2. Japan Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anthrax Vaccine Market

• 12.1. Australia Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anthrax Vaccine Market

• 13.1. Indonesia Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anthrax Vaccine Market

• 14.1. South Korea Anthrax Vaccine Market Overview
• 14.2. South Korea Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anthrax Vaccine Market

• 15.1. Western Europe Anthrax Vaccine Market Overview
• 15.2. Western Europe Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anthrax Vaccine Market

• 16.1. UK Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anthrax Vaccine Market

• 17.1. Germany Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anthrax Vaccine Market

• 18.1. France Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anthrax Vaccine Market

• 19.1. Italy Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anthrax Vaccine Market

• 20.1. Spain Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anthrax Vaccine Market

• 21.1. Eastern Europe Anthrax Vaccine Market Overview
• 21.2. Eastern Europe Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anthrax Vaccine Market

• 22.1. Russia Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anthrax Vaccine Market

• 23.1. North America Anthrax Vaccine Market Overview
• 23.2. North America Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anthrax Vaccine Market

• 24.1. USA Anthrax Vaccine Market Overview
• 24.2. USA Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anthrax Vaccine Market

• 25.1. Canada Anthrax Vaccine Market Overview
• 25.2. Canada Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anthrax Vaccine Market

• 26.1. South America Anthrax Vaccine Market Overview
• 26.2. South America Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anthrax Vaccine Market

• 27.1. Brazil Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anthrax Vaccine Market

• 28.1. Middle East Anthrax Vaccine Market Overview
• 28.2. Middle East Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anthrax Vaccine Market

• 29.1. Africa Anthrax Vaccine Market Overview
• 29.2. Africa Anthrax Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anthrax Vaccine Market, Segmentation By Application Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anthrax Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anthrax Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Anthrax Vaccine Market Competitive Landscape
• 30.2. Anthrax Vaccine Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GC Biopharma Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Emergent BioSolutions Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Indian Immunologicals Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Valneva SE Overview, Products and Services, Strategy and Financial Analysis

31. Anthrax Vaccine Market Other Major And Innovative Companies

• 31.1. PharmAthene Inc
• 31.2. Porton Biopharma Limited
• 31.3. Pfenex Inc.
• 31.4. Choong Ang Vaccine Laboratories Co. Ltd.
• 31.5. Colorado Serum Company, Inc.
• 31.6. Elusys Therapeutics Inc.
• 31.7. SIGA Technologies Inc.
• 31.8. Inovio Pharmaceuticals
• 31.9. Botswana Vaccine Institute
• 31.10. JOVAC
• 31.11. Prokarium
• 31.12. Soligenix Inc.
• 31.13. Vaxart Inc.
• 31.14. DynPort Vaccine Company LLC
• 31.15. VECOL S.A

32. Global Anthrax Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anthrax Vaccine Market

34. Recent Developments In The Anthrax Vaccine Market

35. Anthrax Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Anthrax Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anthrax Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anthrax Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer